Certolizumab pegol in active rheumatoid arthritis

被引：0
|
作者：
Aarat M. Patel
Larry W. Moreland
机构：
[1] University of Pittsburgh,Division of Rheumatology and Clinical Immunology, Division of Pediatric Rheumatology
[2] Children’s Hospital,Division of Rheumatology and Clinical Immunology
[3] University of Pittsburgh,undefined
来源：
Current Rheumatology Reports | 2009年 / 11卷 / 5期
关键词：
Adalimumab; Active Rheumatoid Arthritis; Certolizumab Pegol; ACR20 Response Rate; Total Sharp Score;
D O I：
10.1007/s11926-009-0056-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：311 / 312
页数：1
相关论文
共 50 条
  • [31] Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis
    Morita, Takayoshi
    Fujimoto, Kosuke
    Shima, Yoshihito
    Ogata, Atsushi
    Kumanogoh, Atsushi
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (09)
  • [32] EFFICACY OF THE INITIAL TREATMENT WITH CERTOLIZUMAB PEGOL FOR RHEUMATOID ARTHRITIS: A MULTICENTER STUDY
    Hattori, Y.
    Kaneko, A.
    Kida, D.
    Kanayama, Y.
    Hirano, Y.
    Kanda, H.
    Kojima, T.
    Ishiguro, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 473 - 473
  • [33] DELAYED CUTANEOUS HYPERSENSITIVITY REACTION TO CERTOLIZUMAB PEGOL IN A PATIENT WITH RHEUMATOID ARTHRITIS
    Iammatteo, M.
    Lowes, M.
    Broder, A.
    Jovanovic, B.
    Sarwar, U.
    Jacobson, M.
    Jerschow, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A46 - A47
  • [34] Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
    Tanaka, Yoshiya
    Atsumi, Tatsuya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Shoji, Toshiharu
    Miyasaka, Nobuyuki
    Koike, Takao
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (03) : 316 - 324
  • [35] Certolizumab Pegol: in rheumatoid arthritis (vol 23, pg 407, 2009)
    Duggan, S. T.
    Keam, S. J.
    BIODRUGS, 2010, 24 (01) : 54 - 54
  • [36] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
    Purcaru, O.
    Taylor, P. C.
    Emery, P.
    Palmer, S.
    VALUE IN HEALTH, 2010, 13 (07) : A310 - A310
  • [37] Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis
    Nishimura, Akito
    Minegishi, Yohjiroh
    Kwamura, Keiko
    Ichino, Asako
    Uchiyama, Katsufumi
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (09) : 1601 - 1602
  • [38] Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis
    Domanska, Barbara
    VanLunen, Brenda
    Peterson, Luke
    Mountian, Irina
    Schiff, Michael
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (01) : 15 - 22
  • [39] Optimisation of TNF-Inhibitor Therapy for Rheumatoid Arthritis: Focus on Certolizumab Pegol
    BioDrugs, 2014, 28 (Suppl 1) : 1 - 1
  • [40] Effect of Certolizumab Pegol With Methotrexate on Home and Work Place Productivity and Social Activities in Patients With Active Rheumatoid Arthritis
    Kavanaugh, Arthur
    Smolen, Josef S.
    Emery, Paul
    Purcaru, Oana
    Keystone, Edward
    Richard, Lance
    Strand, Vibeke
    van Vollenhoven, Ronald F.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (11): : 1592 - 1600
12345